Levocarnitine for use in the Treatment of Carnitine Deficiency in ESRD Patients | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for levocarnitine use in the treatment of carnitine deficiency in ESRD patients, effective May 15, 2026. Here's what billing teams need to do before that date.

This is one of those policies that doesn't get a lot of attention until your dialysis-affiliated billers start seeing denials. CMS levocarnitine coverage policy for end-stage renal disease patients has been on the books for years, but this modification signals that CMS is tightening how it defines medical necessity and covered indications for this drug. The policy does not carry a numbered policy code in the traditional NCD or LCD format, but it operates within the CMS Medicare coverage framework governing ESRD-related drug therapies. This policy update directly affects nephrology practices, dialysis facilities, and any billing team submitting levocarnitine claims under Medicare.

Quick-Reference Table

CMS Levocarnitine Coverage Criteria and Medical Necessity Requirements 2026

Levocarnitine coverage under Medicare has always been conditional. CMS does not cover this drug broadly for ESRD patients. Coverage exists specifically when carnitine deficiency is documented and directly linked to dialysis-related depletion.

The core medical necessity argument for levocarnitine in ESRD rests on a well-established clinical reality: hemodialysis removes carnitine from the blood. Patients on long-term dialysis develop low plasma free carnitine levels. That depletion can cause symptoms including muscle weakness, cardiomyopathy, and dialysis-related hypotension. CMS recognizes this pathway — but only under specific documented conditions.

To meet medical necessity under the CMS coverage policy, documentation must show that the patient has a confirmed diagnosis of carnitine deficiency. This is not a case where suspected deficiency or clinical suspicion alone carries a claim. You need labs. Plasma free carnitine levels below the established threshold must appear in the medical record, and the treating physician must tie those levels to the patient's ESRD and dialysis history.

Prior authorization is not universally required for levocarnitine under Medicare Part B, but your Medicare Administrative Contractor — your MAC — may impose additional local coverage requirements. Check with your regional MAC before submitting claims, especially if you're in a jurisdiction that has issued a local coverage determination on ESRD drug therapies. Some MACs have been more aggressive than others in applying coverage restrictions.

This coverage policy also limits the route of administration CMS will reimburse. Intravenous levocarnitine administered during hemodialysis is the route CMS has historically covered. Oral levocarnitine reimbursement under Medicare for ESRD patients is a different — and significantly more contested — matter. If your facility has been billing oral levocarnitine for ESRD patients, this policy modification is a direct signal to review that practice now, before May 15, 2026.

CMS Levocarnitine Exclusions and Non-Covered Indications

CMS does not cover levocarnitine for all carnitine-related claims. The exclusions here are real and carry significant claim denial risk.

Oral levocarnitine for ESRD patients has been a persistent coverage problem. CMS has historically taken the position that oral supplementation is not covered under Part B for this indication. Facilities that bill oral levocarnitine under the same clinical rationale as IV levocarnitine will face denials.

Levocarnitine for non-dialysis ESRD patients — patients who are ESRD-diagnosed but not yet on dialysis or who have transitioned off dialysis — falls outside the covered indication. The coverage policy ties levocarnitine reimbursement specifically to active hemodialysis. If the patient's treatment status has changed, the coverage rationale changes with it.

Use of levocarnitine for conditions unrelated to dialysis-induced carnitine depletion is not covered under this policy. If a physician is prescribing levocarnitine for a different underlying condition in an ESRD patient, the claim needs to be supported by a different coverage pathway — or it won't be covered at all.

Coverage Indications at a Glance

CMS Levocarnitine Billing Guidelines and Action Items 2026

This is the section your billing team actually needs. Here are the steps to take before May 15, 2026.

CPT, HCPCS, and ICD-10 Codes for Levocarnitine Under This CMS Policy

The policy document associated with this modification does not list specific CPT, HCPCS, or ICD-10 codes in the version available at publication. This is not unusual for CMS drug coverage policies — the billing guidelines often reference the applicable HCPCS drug codes separately through fee schedule updates or MAC-level guidance rather than embedding them in the policy itself.

That said, levocarnitine billing under Medicare typically involves HCPCS-level drug codes. Your billing team should verify the correct HCPCS codes with your MAC and confirm that your coding aligns with the route-of-administration distinctions the policy draws. The difference between IV and oral levocarnitine is not just clinical — it's a coverage distinction that will determine whether your claim pays or denies.

Do not substitute codes based on assumptions from prior billing patterns. If this policy modification has changed the coverage criteria, your code-to-diagnosis linkage needs to reflect the updated requirements. Run this by your coding team and your compliance officer together.

Action: Check the full policy source at https://app.payerpolicy.org/p/cms/159-v2 for any code updates posted after publication, and monitor your MAC's LCD page for corresponding HCPCS and ICD-10 code lists.

What This Policy Change Means in Practice

Here's the real issue with this modification: CMS has had a complicated history with levocarnitine coverage for ESRD patients going back decades. The agency has periodically tightened and clarified this coverage policy, and each time it does, facilities that weren't documenting carefully enough take the hit.

This isn't a dramatic expansion or a total reversal. It's a refinement. But refinements in CMS drug coverage policies almost always tighten something — a documentation requirement, a coverage boundary, a prior authorization expectation. The facilities that get caught are the ones that assume their existing process is good enough.

Levocarnitine billing for ESRD is a high-volume, recurring claim pattern at dialysis facilities. If your documentation protocol hasn't been reviewed recently, the May 15, 2026 effective date is the forcing function you need. A claim denial on a recurring drug administration is not a one-time hit — it's a pattern that compounds.

The clinical case for levocarnitine in dialysis patients is legitimate. CMS accepts it. But CMS also requires you to prove it with every claim. That's the bargain. Make sure your billing guidelines, your clinical documentation workflows, and your charge capture are all aligned before the effective date.